Videos

Viviane Boaventura, MD, MsC, PhD, discusses which arbovirus poses the greatest threat to Brazil.

Prof. Francisco Veas, PhD, discusses the launch of a task force dedicated to gaining a better understanding of Lyme disease.

Silvia Munoz-Price, MD, PhD, calls for more microbiome research in order to ultimately improve patient care in hospitals.

James S. Lewis, PharmD, FIDSA, shares different proposals shared in the health care community to incentivize pharmaceutical companies to develop needed drugs.

William Schaffner, MD, discusses how the adults aged 65 and older are disproportionately affected by influenza.

Brinda Emu, MD, offers insight into the HIV monoclonal antibody ibalizumab.

Michael N. Dudley, PharmD, explains how VABOMERE was associated with a higher overall cure rate and lower mortality compared with the best available therapy in patients with CRE infections in a recent trial.

Monica Mahoney, PharmD, BCPS-AQ ID, explains the first-line empiric therapy for candidemia.

Ciara Kennedy, PhD, breaks down APX001, a new antifungal with a unique mechanism of action.

Jessica Justman, MD, shares how the PHIA project is collecting HIV biomarkers in children.

Amanda Paschke, MD, MSCE, explains the advantage of administering a beta-lactam in combination with a beta-lactamase inhibitor.

Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a unique, novel antimicrobial.

Christopher McCoy, PharmD, shares the protocol for approaching patients who may have a beta-lactam allergy.

Sue Cammarata, MD, explains the advantages that delafloxcin has over other fluoroquinolones.

Neil Fishman, MD, explains what the standardized antimicrobial administration ratio is.

Emily Heil, PharmD, BCPS-AQ ID, sheds light on one of the standards of new antibiotic stewardship regulations: all antibiotic orders should include indication for use.

David Andes, MD, shares the half-life and dosing intervals for a new long-acting echinocandin.

Steven Gelone, PharmD, shares the topline data yielded from the LEAP-1 study.

David Huang, PhD, MD, shares the recent results of the REVIVE-2 trial.

Patrick Horn, MD, PhD, explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.

James S. Lewis, PharmD, FIDSA, addresses the issues that surround current antibiotic development.

Viviane Boaventura, MD, MsC, PhD, explains how Zika virus causes auditory loss.

William Schaffner, MD, medical director for the National Foundation for Infectious Diseases’ (NFID), provides a brief overview of the past flu season (2016-2017).

Alan Gross, PharmD, explains how a neural network can help identify patients who are at increased risk for multidrug-resistant pathogens.

Silvia Munoz-Price, MD, PhD, explains why infection control bundles should evolve as the problems faced by hospital epidemiologists continue to change.

Alex Rinehart, PhD, explains how the development of a long-acting injectable offers a new preventive option for HIV.

David A. Schwartz, MD, MS Hyg, FCAP, explains how researchers from all over the world have come together to share their research on Zika virus.

Silvio Pitlik, MD, provides insight into the prevalence of Lyme disease in Israel.